United Therapeutics (NASDAQ:UTHR – Get Free Report) had its price objective hoisted by investment analysts at Oppenheimer from $575.00 to $600.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s price target indicates a potential upside of 61.04% from the stock’s […]

Biogen (NASDAQ:BIIB – Get Free Report) had its target price decreased by investment analysts at Oppenheimer from $270.00 to $255.00 in a note issued to investors on Thursday, Benzinga reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s price objective indicates a potential upside of 44.59% from the company’s current […]